The interval between non-small cell lung cancer and brain metastasis affects the prognosis of patients

Deborah RSmith of the Department of Radiation Oncology at Columbia University's Irvine Medical Center and others study the effects of brain metastasis in non-small cell lung cancer on prognosis, and the results are published in the May 2019 issue of Journal of Neuro-Neuro-Neuroy- Excerpted from the article(Ref: Smith DR, et alJ Neurooncol2019 May;143 (1):145-155doi: 10.1007/s11060-019-03149-4Epub 2019 Mar 14non-small cell lung cancer (NSCLC) is good brain metastasis and is closely related to mortalityWith the remarkable improvement of the treatment effect of lung cancer, NSCLC brain metastasis has become an important clinical problemDeborah RSmith of the Department of Radiation Oncology at Columbia University's Irvine Medical Center and others study the effects of brain metastasis in non-small cell lung cancer on prognosis, and the results are published in the May 2019 issue of Journal of Neuro-Neuro-Neuroythe study reviewed 105 cases of NSCLC brain metastasis after radiotherapy between 1997 and 2015When the diagnosis of NSCLC is excluded, there is an incomplete brain metastasis and NSCLS staging informationThe effect of nSCLC brain metastasis on patient survival was analyzed using Kaplan-Meier and multi-factor Cox regression105 patients had an average age of 62 years and a median follow-up time of 10.6 yearsNSCLC phased phases I, II, III and IV patients accounted for 13.3%, 13.3%, 37.1% and 36.2%, respectively 61.0% were Caucasian and 81.9% were lung adenocarcinoma In 72 cases, EGFR-, KRAS-and ALK mutations were 22.2%, 16.7% and 6.9%, respectively NSCLC staging and the interval between brain metastasis was significantly correlated, with median intervals of 29 months, 19 months, 16 months and 13 months for brain metastasis in patients in phase I to IV, respectively The multi-factor Cox regression analysis confirms that the higher the NSCLC staging, the earlier brain metastasis occurs (phase II HR? 1.602, PHASE III HR s 2.874, IV period HR s 3.501; p?016) Non-adenocarcinoma (HR 3.036, P 0.001), NSCLC unoperated (HR?1.609, P-0.036) and unsystematic treatment (HR-3.560, P-0.004) are all independent factors of NSCLC's early brain metastasis the median survival of Brain Metastasis in NSCLC was 16 months (95% CI, 9.4-22.6) The survival time after brain transfer was related to NSCLC phased (P-0.042), and the median survival time after I.-IV period was 31 months, 26 months, 11 months and 8 months, respectively The multi-factor Cox regression analysis showed that the late mortality rate of brain metastasis was low (HR -0.970; 95% CI, 0.957-0.984; P 0.001) single-factor Cox regression analysis showed that the factors significantly related to the decline in survival rate after brain metastasis in NSCLC, including lung cancer-specific graded prognosis score (GPA), advanced age, low Karnofsky score, high NSCLC staging at first diagnosis, concurrent intracranial metastasis, poor local treatment of intracranial lesions or no early surgery Multivariate Cox regression confirms that low GPA score is associated with high survival after brain metastasis (HR?0.531; 95% CI, 0.390-0.724; P 0.001); concurrent extracranial transfer (HR?1.842; 95% CI, 1.083-3.132; P.0.02442) ), patients with poor intracranial lesions (HR 3.320; 95% CI, 1.938-5.688; P 0.001) and pathology were non-adenocarcinomas (HR-3.031; 95% CI, 1.643-5.595; P 0.001) increased risk of death.